Circassia Limited
37
0
0
35
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.4%
2 terminated/withdrawn out of 37 trials
94.6%
+8.1% vs industry average
5%
2 trials in Phase 3/4
11%
4 of 35 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Role: collaborator
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
Role: collaborator
Phase III Cat-PAD Follow-on Study
Role: lead
Phase II HDM-SPIRE Safety and Efficacy Study
Role: lead
Phase III Cat-PAD Study
Role: lead
Paediatric Safety Study in Cat-PAD
Role: lead
Birch-SPIRE Safety and Efficacy Study
Role: lead
Efficacy and Safety of Grass-SPIRE Registration Study
Role: lead
Ragweed-SPIRE Follow-On Study
Role: lead
Grass Observational Study
Role: lead
Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma
Role: lead
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
Role: lead
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
Role: lead
ToleroMune Grass Follow on Study
Role: lead
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Role: lead
ToleroMune House Dust Mite (HDM) Tolerability Study
Role: lead
An Optional Investigation of Biomarkers of Efficacy
Role: lead
ToleroMune House Dust Mite Follow on Study
Role: lead
House Dust Mite Observational Study
Role: lead
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
Role: lead